Literature DB >> 15696320

The effects of CRF antagonists, antalarmin, CP154,526, LWH234, and R121919, in the forced swim test and on swim-induced increases in adrenocorticotropin in rats.

Emily M Jutkiewicz1, Susan K Wood, Hani Houshyar, Ling-Wei Hsin, Kenner C Rice, James H Woods.   

Abstract

RATIONALE: Exposure to extreme stress has been suggested to produce long-term, detrimental alterations in the hypothalamic-pituitary-adrenal (HPA) axis leading to the development of mental disorders such as depression. Therefore, compounds that block the effects of stress hormones were investigated as potential therapeutics for depression.
OBJECTIVES: In the present study, we compared the potential antidepressant-like effects of four CRF antagonists, antalarmin, CP154,526, R121919, and LWH234 (at 3, 10, and 30 mg/kg i.p., 60 min prior to the forced swim test) and the corresponding effect on swim-induced HPA activation to better elucidate the relation between HPA activity and antidepressant activity.
METHODS: The antidepressant-like effects of the CRF antagonists and known antidepressants were determined in the rat forced swim test, and blood samples were obtained before and after swimming for the evaluation of adrenocorticotropin-releasing hormone (ACTH) levels.
RESULTS: Antalarmin, CP154,526, and R121919 did not produce antidepressant-like effects in the forced swim test although these compounds decreased swim-induced increases in ACTH to various extents. In contrast, LWH234 reduced immobility in the forced swim test, without altering the swim-stress-induced ACTH response. However, this compound antagonized restraint-induced ACTH release.
CONCLUSIONS: These data suggest that reducing stress-induced increases in HPA activity alone may not be sufficient to produce antidepressant-like activity; however, reductions in HPA activity may contribute to antidepressant actions of some treatments. In addition, it is proposed that CRF antagonists may alter differentially the HPA axis depending on the type of stressor used or behavioral measure evaluated.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15696320      PMCID: PMC1315297          DOI: 10.1007/s00213-005-2164-z

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  38 in total

1.  Discovery of antidepressant activity by forced swimming test may depend on pre-exposure of rats to a stressful situation.

Authors:  F Borsini; A Lecci; A Sessarego; R Frassine; A Meli
Journal:  Psychopharmacology (Berl)       Date:  1989       Impact factor: 4.530

Review 2.  Regulation of hypophysiotropic factors mediating ACTH secretion.

Authors:  P M Plotsky
Journal:  Ann N Y Acad Sci       Date:  1987       Impact factor: 5.691

3.  Active behaviors in the rat forced swimming test differentially produced by serotonergic and noradrenergic antidepressants.

Authors:  M J Detke; M Rickels; I Lucki
Journal:  Psychopharmacology (Berl)       Date:  1995-09       Impact factor: 4.530

4.  Dexamethasone suppresses pituitary-adrenal but not behavioral effects of centrally administered CRF.

Authors:  D R Britton; M Varela; A Garcia; M Rosenthal
Journal:  Life Sci       Date:  1986-01-20       Impact factor: 5.037

Review 5.  The role of vasopressin in hypothalamo-pituitary-adrenal axis activation during stress: an assessment of the evidence.

Authors:  Gábor B Makara; Zsuzsa Mergl; Dóra Zelena
Journal:  Ann N Y Acad Sci       Date:  2004-06       Impact factor: 5.691

6.  Association of fluoxetine treatment with reductions in CSF concentrations of corticotropin-releasing hormone and arginine vasopressin in patients with major depression.

Authors:  M D De Bellis; P W Gold; T D Geracioti; S J Listwak; M A Kling
Journal:  Am J Psychiatry       Date:  1993-04       Impact factor: 18.112

7.  Antidepressant effects of citalopram and CRF receptor antagonist CP-154,526 in a rat model of depression.

Authors:  David H Overstreet; Adam Keeney; Sandra Hogg
Journal:  Eur J Pharmacol       Date:  2004-05-25       Impact factor: 4.432

8.  Activating and 'anxiogenic' effects of corticotropin releasing factor are not inhibited by blockade of the pituitary-adrenal system with dexamethasone.

Authors:  K T Britton; G Lee; R Dana; S C Risch; G F Koob
Journal:  Life Sci       Date:  1986-10-06       Impact factor: 5.037

9.  Antidepressant-like activity of corticotropin-releasing factor type-1 receptor antagonists in mice.

Authors:  Darci M Nielsen; Galen J Carey; Lisa H Gold
Journal:  Eur J Pharmacol       Date:  2004-09-19       Impact factor: 4.432

Review 10.  Corticotropin-releasing factor in brain: a role in activation, arousal, and affect regulation.

Authors:  Stephen C Heinrichs; George F Koob
Journal:  J Pharmacol Exp Ther       Date:  2004-08-05       Impact factor: 4.030

View more
  31 in total

Review 1.  Evidence for the role of corticotropin-releasing factor in major depressive disorder.

Authors:  R Parrish Waters; Marion Rivalan; D A Bangasser; J M Deussing; M Ising; S K Wood; F Holsboer; Cliff H Summers
Journal:  Neurosci Biobehav Rev       Date:  2015-08-10       Impact factor: 8.989

2.  Treatment with CRH-1 antagonist antalarmin reduces behavioral and endocrine responses to social stressors in marmosets (Callithrix kuhlii).

Authors:  Jeffrey A French; Jeffrey E Fite; Heather Jensen; Katie Oparowski; Michael R Rukstalis; Holly Fix; Brenda Jones; Heather Maxwell; Molly Pacer; Michael L Power; Jay Schulkin
Journal:  Am J Primatol       Date:  2007-08       Impact factor: 2.371

3.  Corticotropin-releasing factor receptor 1 antagonist alters regional activation and effective connectivity in an emotional-arousal circuit during expectation of abdominal pain.

Authors:  Catherine S Hubbard; Jennifer S Labus; Joshua Bueller; Jean Stains; Brandall Suyenobu; George E Dukes; Dennis L Kelleher; Kirsten Tillisch; Bruce D Naliboff; Emeran A Mayer
Journal:  J Neurosci       Date:  2011-08-31       Impact factor: 6.167

Review 4.  Behavioral, biological, and chemical perspectives on targeting CRF(1) receptor antagonists to treat alcoholism.

Authors:  Eric P Zorrilla; Markus Heilig; Harriet de Wit; Yavin Shaham
Journal:  Drug Alcohol Depend       Date:  2013-01-05       Impact factor: 4.492

5.  A corticotropin-releasing factor receptor antagonist improves urodynamic dysfunction produced by social stress or partial bladder outlet obstruction in male rats.

Authors:  Susan K Wood; Kile McFadden; Tagan Griffin; John H Wolfe; Stephen Zderic; Rita J Valentino
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2013-04-03       Impact factor: 3.619

Review 6.  Development of CRF1 receptor antagonists as antidepressants and anxiolytics: progress to date.

Authors:  Glenn R Valdez
Journal:  CNS Drugs       Date:  2006       Impact factor: 5.749

7.  Sex differences in corticotropin-releasing factor receptor-1 action within the dorsal raphe nucleus in stress responsivity.

Authors:  Alexis R Howerton; Alison V Roland; Jessica M Fluharty; Anikò Marshall; Alon Chen; Derek Daniels; Sheryl G Beck; Tracy L Bale
Journal:  Biol Psychiatry       Date:  2013-10-23       Impact factor: 13.382

8.  Essential Role of Ovarian Hormones in Susceptibility to the Consequences of Witnessing Social Defeat in Female Rats.

Authors:  Julie E Finnell; Brandon L Muniz; Akhila R Padi; Calliandra M Lombard; Casey M Moffitt; Christopher S Wood; L Britt Wilson; Lawrence P Reagan; Marlene A Wilson; Susan K Wood
Journal:  Biol Psychiatry       Date:  2018-01-31       Impact factor: 13.382

9.  Corticotropin-releasing factor-1 receptor antagonists decrease heroin self-administration in long- but not short-access rats.

Authors:  Thomas N Greenwell; Cindy K Funk; Pietro Cottone; Heather N Richardson; Scott A Chen; Kenner C Rice; Eric P Zorrilla; George F Koob
Journal:  Addict Biol       Date:  2009-04       Impact factor: 4.280

Review 10.  Role of CRF receptor signaling in stress vulnerability, anxiety, and depression.

Authors:  Richard L Hauger; Victoria Risbrough; Robert H Oakley; J Alberto Olivares-Reyes; Frank M Dautzenberg
Journal:  Ann N Y Acad Sci       Date:  2009-10       Impact factor: 5.691

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.